Moderna: Vaccine Produced Strong Immune Results In Kids

Moderna's trial results indicate that smaller doses of their vaccine generate a strong immune response in children aged 6 to 11, with antibody response noted a month after the second dose. Although not yet peer-reviewed, Moderna plans to submit these findings to the FDA. Meanwhile, Pfizer is prepared to distribute its vaccine for children aged 5 to 11, pending FDA authorization. The FDA has indicated that the benefits of the vaccine outweigh the risks. According to the American Academy of Pediatrics, over 6 million children in the US have contracted COVID-19 since the pandemic began, out of 45 million total cases nationwide.

What age group did Moderna's trial focus on for their COVID-19 vaccine?

• Children aged 2 to 5

• Children aged 6 to 11

• Adults aged 18 and above

• Teenagers aged 12 to 15

When did Moderna observe the antibody response after the second dose?

• Immediately after the first dose

• One week after the second dose

• One month after the second dose

• Three months after the second dose

What is Pfizer's plan if the FDA approves their vaccine for children?

• Wait for CDC approval

• Ship doses immediately

• Conduct more trials

• Start a new marketing campaign

How many children in the US have tested positive for COVID-19 since the pandemic began?

• More than 6 million

• More than 3 million

• More than 10 million

• More than 1 million

What is the total number of COVID-19 cases reported across the US?

• 45 million

• 15 million

• 60 million

• 30 million